Skip to main content
Log in

Comment on Fu, J. and Chen, Y.: The efficacy and safety of 5 mg/d vortioxetine compared to placebo for major depressive disorder: a meta-analysis

  • Letter to the Editor
  • Published:
Psychopharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  • Alvarez E, Perez V, Dragheim M, Loft H, Artigas F (2012) A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol 15(5):589–600

    Article  CAS  PubMed  Google Scholar 

  • Fu J, Chen Y (2015) The efficacy and safety of 5 mg/d vortioxetine compared to placebo for major depressive disorder: a meta-analysis. Psychopharmacol 232(1):7–16

    Article  CAS  Google Scholar 

  • Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME (2012) A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry 73(7):953–959

    Article  CAS  PubMed  Google Scholar 

  • Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME (2013) A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol 16(2):313–321

    Article  CAS  PubMed  Google Scholar 

  • Katona C, Hansen T, Olsen CK (2012) A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 27(4):215–223

    Article  PubMed  Google Scholar 

  • Mahableshwarkar AR, Jacobsen PL, Chen Y (2013) A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin 29(3):217–226

    Article  CAS  PubMed  Google Scholar 

  • Thase ME, Mahableshwarkar AR, Dragheim M, Loft H, Vieta E (2016) A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol 26(6):979–993

    Article  CAS  PubMed  Google Scholar 

  • The UK ECT Review Group (2003) Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 361(9360):799–808

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Eduardo C. Humes.

Ethics declarations

Conflict of interest

Dr. Humes received travel grant from Lundbeck Brasil LTDA to attend 2015 Annual APA Meeting in Toronto, Canada.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Humes, E.C., Brunoni, A.R. Comment on Fu, J. and Chen, Y.: The efficacy and safety of 5 mg/d vortioxetine compared to placebo for major depressive disorder: a meta-analysis. Psychopharmacology 234, 903–904 (2017). https://doi.org/10.1007/s00213-017-4531-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-017-4531-y

Keywords

Navigation